Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Apr 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a thorough evaluation of elderly patients can help improve the success of a specific type of treatment called allogeneic hematopoietic stem cell transplantation (allo-HSCT). This treatment is often used for patients with blood disorders, and the trial aims to identify factors that may affect how well patients do after the transplant. By looking at various aspects related to the patient, their disease, the donor, and the treatment itself, researchers hope to find ways to enhance outcomes for older adults undergoing this procedure.

To be eligible for this trial, participants need to be at least 55 years old and have a blood disorder that is suitable for transplantation. They also must be willing to give their consent to participate. However, individuals who are pregnant, have uncontrolled infections, or are found to be unsuitable for the transplant by the study team will not be able to take part. Although the trial is not currently recruiting participants, those who do join can expect to be closely evaluated to better understand their health and how it relates to their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (a)Age ≥55 years.
• • (b)Hematologic disorders with established indications for transplantation, including malignant and non-malignant hematologic diseases. (c)Willingness to provide informed consent.
• • Exclusion Criteria: (a)Pregnancy. (b) Uncontrolled active infection. (c) Lack of informed consent. (d)Deemed ineligible for transplantation after investigator assessment